Neutralizing antibodies are known to have a crucial role in protecting against SARS-CoV-2
infection and have been suggested to be a useful correlate of protection for vaccine clinical …

The highly transmissible Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first detected in late 2021. Initial Omicron waves were …

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Omicron sublineages, including the BA. 2-derived BA. 2.75. 2 and the BA. 5-derived BQ. 1.1 …

The continued evolution of SARS-CoV-2 has led to the emergence of several new Omicron
subvariants, including BQ. 1, BQ. 1.1, BA. 4.6, BF. 7, and BA. 2.75. 2. Here, we examine the …

We report that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta spike
mutation P681R plays a key role in the Alpha-to-Delta variant replacement during the …

Omicron subvariants continuingly challenge current vaccination strategies. Here, we
demonstrate nearly complete escape of the XBB. 1.5, CH. 1.1, and CA. 3.1 variants from …

Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA. 1, BA. 1.1, and BA. 2,
have reignited concern over potential escape from vaccine-and infection-induced immunity …

Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we
characterized BA. 2.86 and XBB-derived variant FLip by investigating their neutralization …

We examined antibody and memory B cell responses longitudinally for∼ 9–10 months after
primary 2-dose SARS-CoV-2 mRNA vaccination and 3 months after a 3rd dose. Antibody …

Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the
pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV …